Translate Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 13th of September, 2021.
74 hedge funds and large institutions have $525M invested in Translate Bio, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 17 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
25% more capital invested
Capital invested by funds: $421M → $525M (+$103M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 77 → 74 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$3.18M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$2.17M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.79M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.58M |
| 5 |
State Street
Boston,
Massachusetts
|
+$760K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.46M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.02M |
| 3 |
AG
Artal Group
Luxembourg
|
-$410K |
| 4 |
Morgan Stanley
New York
|
-$300K |
| 5 |
AGM
Alpine Global Management
New York
|
-$266K |
TBIO Hedge Fund Activity: Q1 2020 in Review
74 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q1 2020, worth a combined $525M — up 25% from $421M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TBIO and 14 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 26 added.
The largest buyer was RTW Investments, adding an estimated $3.18M. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $1.46M sold.
- 74 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q1 2020, down from 77 in Q4 2019.
- Funds reported $525M of Translate Bio, Inc. Common Stock stock for Q1 2020, up 25% quarter-over-quarter.
- 14 funds opened new Translate Bio, Inc. Common Stock positions in Q1 2020 and 17 closed out, a net change of -3 holders.
- The largest Translate Bio, Inc. Common Stock buyer in Q1 2020 was RTW Investments, an estimated $3.18M added.
- The largest Translate Bio, Inc. Common Stock seller in Q1 2020 was DAFNA Capital Management, an estimated $1.46M sold.
Based on aggregated 13F filings for Q1 2020.